| 2024年中报 | 2023年年报 | 2023年中报 | 2022年年报 | |
|---|---|---|---|---|
| 营业收入(元) | ||||
| 结核菌素纯蛋白衍生物(元) | - | - | 339,898,984.53 | 609,035,932.84 |
| 卡介菌纯蛋白衍生物(元) | - | - | 7,285,097.96 | 28,777,655.42 |
| 试剂盒及其他(元) | - | - | 654,683.49 | 2,324,673.31 |
| 结核菌素纯蛋白衍生物(50IU/ml.1ml/支)(元) | - | 557,418,351.77 | - | - |
| 结核菌素纯蛋白衍生物(TB-PPD)20IU/ml.1ml/支(元) | - | 69,093,973.72 | - | - |
| 卡介菌纯蛋白衍生物(BCG-PPD)50IU/ml.1ml/支(元) | - | 25,118,455.98 | - | - |
| 结核菌素纯蛋白衍生物(TB-PPD)销售收入(元) | 384,581,465.30 | - | - | - |
| 卡介菌纯蛋白衍生物(BCG-PPD)销售收入(元) | 7,641,649.78 | - | - | - |
| 试剂盒销售收入(元) | 81,281.55 | - | - | - |
| 医药推广收入(元) | 6,903,018.87 | - | - | - |
| 其他(元) | - | 1,259,930.96 | - | - |
| 营业成本(元) | ||||
| 结核菌素纯蛋白衍生物(元) | - | - | 13,859,998.47 | 19,441,034.11 |
| 卡介菌纯蛋白衍生物(元) | - | - | 1,417,722.82 | 4,581,302.83 |
| 试剂盒及其他(元) | - | - | 245,233.53 | 484,303.17 |
| 结核菌素纯蛋白衍生物(50IU/ml.1ml/支)(元) | - | 16,135,911.17 | - | - |
| 结核菌素纯蛋白衍生物(TB-PPD)20IU/ml.1ml/支(元) | - | 6,551,295.69 | - | - |
| 卡介菌纯蛋白衍生物(BCG-PPD)50IU/ml.1ml/支(元) | - | 3,680,384.57 | - | - |
| 结核菌素纯蛋白衍生物(TB-PPD)销售收入(元) | 13,116,275.36 | - | - | - |
| 卡介菌纯蛋白衍生物(BCG-PPD)销售收入(元) | 1,280,787.73 | - | - | - |
| 试剂盒销售收入(元) | 29,520.67 | - | - | - |
| 医药推广收入(元) | 3,747,860.48 | - | - | - |
| 其他(元) | - | 277,766.80 | - | - |
| 毛利(元) | ||||
| 结核菌素纯蛋白衍生物(元) | - | - | 326,038,986.06 | 589,594,898.73 |
| 卡介菌纯蛋白衍生物(元) | - | - | 5,867,375.14 | 24,196,352.59 |
| 试剂盒及其他(元) | - | - | 409,449.96 | 1,840,370.14 |
| 结核菌素纯蛋白衍生物(50IU/ml.1ml/支)(元) | - | 541,282,440.60 | - | - |
| 结核菌素纯蛋白衍生物(TB-PPD)20IU/ml.1ml/支(元) | - | 62,542,678.03 | - | - |
| 卡介菌纯蛋白衍生物(BCG-PPD)50IU/ml.1ml/支(元) | - | 21,438,071.41 | - | - |
| 结核菌素纯蛋白衍生物(TB-PPD)销售收入(元) | 371,465,189.94 | - | - | - |
| 卡介菌纯蛋白衍生物(BCG-PPD)销售收入(元) | 6,360,862.05 | - | - | - |
| 试剂盒销售收入(元) | 51,760.88 | - | - | - |
| 医药推广收入(元) | 3,155,158.39 | - | - | - |
| 其他(元) | - | 982,164.16 | - | - |
| 毛利率(%) | ||||
| 结核菌素纯蛋白衍生物(%) | - | - | 95.92 | 96.81 |
| 卡介菌纯蛋白衍生物(%) | - | - | 80.54 | 84.08 |
| 试剂盒及其他(%) | - | - | 62.54 | 79.17 |
| 结核菌素纯蛋白衍生物(50IU/ml.1ml/支)(%) | - | 97.11 | - | - |
| 结核菌素纯蛋白衍生物(TB-PPD)20IU/ml.1ml/支(%) | - | 90.52 | - | - |
| 卡介菌纯蛋白衍生物(BCG-PPD)50IU/ml.1ml/支(%) | - | 85.35 | - | - |
| 结核菌素纯蛋白衍生物(TB-PPD)销售收入(%) | 96.59 | - | - | - |
| 卡介菌纯蛋白衍生物(BCG-PPD)销售收入(%) | 83.24 | - | - | - |
| 试剂盒销售收入(%) | 63.68 | - | - | - |
| 医药推广收入(%) | 45.71 | - | - | - |
| 其他(%) | - | 77.95 | - | - |
| 收入构成(%) | ||||
| 结核菌素纯蛋白衍生物(%) | - | - | 97.72 | 95.14 |
| 卡介菌纯蛋白衍生物(%) | - | - | 2.09 | 4.50 |
| 试剂盒及其他(%) | - | - | 0.19 | 0.36 |
| 结核菌素纯蛋白衍生物(50IU/ml.1ml/支)(%) | - | 85.38 | - | - |
| 结核菌素纯蛋白衍生物(TB-PPD)20IU/ml.1ml/支(%) | - | 10.58 | - | - |
| 卡介菌纯蛋白衍生物(BCG-PPD)50IU/ml.1ml/支(%) | - | 3.85 | - | - |
| 结核菌素纯蛋白衍生物(TB-PPD)销售收入(%) | 96.34 | - | - | - |
| 卡介菌纯蛋白衍生物(BCG-PPD)销售收入(%) | 1.91 | - | - | - |
| 试剂盒销售收入(%) | 0.02 | - | - | - |
| 医药推广收入(%) | 1.73 | - | - | - |
| 其他(%) | - | 0.19 | - | - |
| 毛利构成(%) | ||||
| 结核菌素纯蛋白衍生物(%) | - | - | 98.11 | 95.77 |
| 卡介菌纯蛋白衍生物(%) | - | - | 1.77 | 3.93 |
| 试剂盒及其他(%) | - | - | 0.12 | 0.30 |
| 结核菌素纯蛋白衍生物(50IU/ml.1ml/支)(%) | - | 86.43 | - | - |
| 结核菌素纯蛋白衍生物(TB-PPD)20IU/ml.1ml/支(%) | - | 9.99 | - | - |
| 卡介菌纯蛋白衍生物(BCG-PPD)50IU/ml.1ml/支(%) | - | 3.42 | - | - |
| 结核菌素纯蛋白衍生物(TB-PPD)销售收入(%) | 97.49 | - | - | - |
| 卡介菌纯蛋白衍生物(BCG-PPD)销售收入(%) | 1.67 | - | - | - |
| 试剂盒销售收入(%) | 0.01 | - | - | - |
| 医药推广收入(%) | 0.83 | - | - | - |
| 其他(%) | - | 0.16 | - | - |